Richmond, Va.
Boehringer Ingelheim Pharmaceuticals is planning a new 16-researcher R&D lab for pharmaceutical synthesis in Richmond's Virginia Biotechnology Research Park. Over the next five years, Boehringer plans to invest $2.5 million in the facility. Based in Germany, Boehringer's U.S. headquarters are in Connecticut.
